



FLORIDA SOCIETY OF CLINICAL ONCOLOGY FAX BLAST – July 31, 2007

PROGRAM COMMITTEE: Gerardo Colon-Otero, MD, Chairman

FLASCO extends a special thanks to Astra Zeneca for providing the Regional Conferences on Pay for Performance and PQRI which were held around the state last week. The presenter was Dale Meyer from the Lash Group. Most of the major practices and major cancer centers from around the state were represented at these conferences.

LEGISLATIVE COMMITTEE: Lowell Hart, MD, Chairman

FLASCO extends a special thanks to the following Florida Congressmen for co-sponsoring legislation actively supported by our State Society.

H.R. 1078 – The Comprehensive Cancer Care Improvement Act:
Co-Sponsor(s) Rep. Robert Wexler

H. R. 2842 - The Children’s Health Promotion Act of 2007
Co-Sponsor(s) Rep. Debbie Wasserman Schultz

H.R. 1293 - The Access to Medicare Imaging Act of 2007
Co-Sponsors Rep. F. Allen Boyd Rep. Corrine Brown
Rep. Ginny Brown Waite Rep. Rick Keller
Rep. John Mica Rep. Jeff Miller
Rep. Gus Bilirakis

H.R. 1190 - The Community Cancer Care Preservation Act of 2007
Co-Sponsors Rep. Alcee Hastings Rep. Corrine Brown
Rep. Ginny Brown Waite Rep. Kendrick Meek
Rep. Ileana Ros-Lehtinen Rep. Robert Wexler

FLASCO CLINICAL PRACTICE COMMITTEE UPDATE: Thomas Gaddis, MD, Chairman

CMS has requested comment on the proposed changes to Monitoring of ESAs for Beneficiaries with End Stage Renal Disease. The public comment period is from 7/20/2007 ending 8/19/2007. To access the complete document go to: http://www.cms.hhs.gov/mcd/ncpc_view_document.asp?id=11

Of particular interest are the changes to the maximum amounts of Aranesp and Procrit per month. To comment click in the orange comment box at the end of the article title. Comments already received have been posted to the site for your review.

FIRST COAST SERVICE UPDATES:

Incorrect Denial of Claims for ICD-9-CM Code

As a result of a processing issue, claims may have been denied for the ICD-9-CM code submitted. The result is an underpayment situation for claims processed between July 1, 2007, and July 22, 2007. The problem was corrected on July 23, 2007

Incorrect Processing for Some Physician Quality Reporting Initiative (PQRI) Services

Claims for PQRI services submitted with modifiers 1P, 2P, 3P or 8P processed July 1, 2007 through July 23, 2007, may have denied incorrectly with message PR-B18 (Payment adjusted because this procedure code and modifier were invalid on the date of service).

Updated Information for Medicare Providers on National Provider Identifier -

http://www.floridamedicare.com/Part_B/Articles/109473.asp

CMS UPDATES:

Monitoring ESAs Open for Public Comment

Monitoring of Erythropoietin Stimulating Agents for Beneficiaries with End Stage Renal Disease

CMS is requesting public comment on this policy

https://www.cms.hhs.gov/mcd/ncpc_view_document.asp?id=11

MEDICAID UPDATES:

Revised Codes for Immune Globulins

Effective on and after July 1, 2007, Florida Medicaid will no longer reimburse for J1567, injection, immune globulin, intravenous, non-lyophilized, 500 mg. The following HCPCS codes will be used and require a prior authorization: Q4087, Octagam Injection, reimbursement \$107.52; Q4088, Gammagard Liquid Injection, reimbursement \$78.00; Q4091, Flebogamma Injection, reimbursement \$17.00; and Q4092, Gamunex Injection, reimbursement \$68.00. Also, Q4089, Rhophylac Injection, reimbursement \$169.60 and Q4090, Hepagam B Injection, reimbursement \$154.65 will be payable on and after July 1, 2007. Q4089 and A4090 do not require a prior authorization.

MLN MATTERS:

New

MM5700 – Modification to the National Monitoring Policy for Erythropoiesis Stimulating Agents (ESAs) for End-Stage Renal Disease (ESRD) Patients Treated in Renal Dialysis Facilities

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5700.pdf>

MLN Matters Number: MM5586

Electronic Funds Transfer Standardizations and Revisions to the Medicare Claims Processing Manual (Chapter 24) <http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5586.pdf>

USP DI UPDATES:

Nexavar - Accepted - [Advanced hepatocellular carcinoma]

CORPORATE MEMBERSHIP/SPONSORSHIP: (January 1 – December 31, 2007)

FLASCO Members extends a big thanks to all of our 2007 Corporate Members/Sponsors

PLATINUM

Astra Zeneca
Genentech
Oncology Supply/ION
Sanofi-Aventis
Bristol-Myers Squibb
Eli Lilly
Bayer/Onyx
Ortho Biotech
Abraxis Oncology

GOLD

Cephalon Oncology
Pharmion Corporation
OSI Pharmaceuticals
GlaxoSmithKline
Roche
Pfizer
Amgen

SILVER

Genomic Health, Inc.
Talecris Biotherapeutics
Millennium
Celgene
Novartis

BRONZE

Oncology Pharmaceutical Services

FLASCO EVENTS:

July 31 – August 4, 2007 – Mayo Clinic’s 17th Annual Hematology/Oncology Reviews – The Ritz Carlton, Amelia Island
– visit: www.mayo.edu/cme for additional information and registration

Sept. 13-16, 2007 – Joint Cancer Conference – The Breakers, Palm Beach

November 9-10, 2007 – FLASCO Fall Meeting – Rosen Shingle Creek – Orlando

March 7-8, 2008 – FLASCO Spring Meeting – Tampa Airport Marriott Hotel

November 7-8, 2008 – FLASCO Fall Meeting – Location TBD

OTHER EVENTS:

The Florida Association of Pediatric Tumor Programs will hold its 30th Anniversary Annual Seminar at the Hyatt Regency Grand Cypress in Orlando from November 15-17, 2007. To register please visit the following Web Site: www.fapt.org

FLASCO Contact Information:

Dorothy Green Phillips, Executive Director - 3709 W. Jetton Ave., Tampa, Florida 33629

Tel: 800.444.1410, Ext. 4410 - Cell Phone: 813.294.2620 - Fax: 813.254.5857 or 813.349.4472

Email: Dorothy.Green@cancer.org